Abstract:Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) is a rare inherited neurodegenerative disorder, and most patients with FTDP-17 are caused by mutation of microtubule-associated protein tau (MAPT) gene. Biomarkers study of FTDP-17 showed that temporal lobe hypometabolism appeared prior to clinical symptoms. However, it remains unclear whether dopamine transporter (DAT) distribution, which is potentially related to the parkinsonism in FTDP-17, could predict the onset of disease. In our study, 5 participants including 2 affected patients and 3 asymptomatic mutation carriers were enrolled from a gene-confirmed (N279K mutation) FTDP-17 pedigree from October 2014 and November 2014 for brain metabolism and DAT distribution investigation. Each participant was assessed through standardized clinical evaluation (clinical history, physical examination, MRI, lumbar puncture, etc.), neuropsychology assessment (memory, executive function, speech, naming, etc.), as well as FBI (Frontal Behavioral Inventory, FBI) and UPDRS (Unified Parkinson Disease Rating Scale, UPDARS). Brain metabolism and DAT distribution were estimated by [18F]fludeoxyglucose (FDG) SPECT and [11C]CFT PET, respectively. Clinical, neuropsychology, neuroimaging, and genetic features of 5 participants were listed in Table 1. Parkinsonism was the first symptom for both 2 patients. Personality, speech changes and dementia accompanied with brain atrophy were developed at the later stage in one patient. 3 asymptomatic carriers showed no clinical, neuropsychology or structural imaging abnormality. (2) The [18F]FDG SPECT studies illustrated asymmetric hypometabolism of the temporal lobes in 5 participants. In addition, hypometabolism of the frontal lobes and parietal lobes were seen in 2 affected patients and 2 mutation carriers, and basal ganglia changes were observed in 2 affected patients. (3) Regarding to the [11C]CFT PET, all the 4 examined participants (2 affected patients and 2 mutation carriers) showed asymmetric decreased uptake of tracer in basal ganglia regions (Figure 2). Pedigree of the FTDP-17 family with MAPT N279K mutation Brain metabolism of an affected participant (A) and an at-risk asymptomatic mutation carrier (B) DAT distribution at basal ganglia of an affected participant (A) and an at-risk asymptomatic mutation carrier (B) The feature of brain hypometabolism and decreased DAT can predict the disease at least 15 years before the onset of the elder generation of patients, and 7 years before the onset of peer of patients. Therefore, brain metabolism and DAT distribution could be a potential biomarker in early diagnosis of FTDP-17, even at the asymptomatic stage.

A Peculiar Tau Accumulation Pattern Identified Via 18 F-Florzolotau PET Imaging in a Patient With Frontotemporal Dementia Caused by a Mutation in the MAPT Gene

Tau PET Imaging with [18F]PM-PBB3 in Frontotemporal Dementia with MAPT Mutation.

Tau PET With 18F-THK-5351 Taiwan Patients With Familial Alzheimer's Disease With the APP p.D678H Mutation

In Vivo18F‐APN‐1607 Tau Positron Emission Tomography Imaging in MAPT Mutations: Cross‐Sectional and Longitudinal Findings

In Vivo 18 F‐APN ‐1607 Tau Positron Emission Tomography Imaging in MAPT Mutations: Cross‐Sectional and Longitudinal Findings

P3‐148: Brain Hypometabolism and Decreased Dopamine Transporter Distribution in Asymptomatic MAPT N279K Mutation Carriers in Familial FTDP‐17 Pedigree from China

18F‐Florzolotau PET Imaging Unveils Tau Pathology in Dementia with Lewy Bodies

MAPT Rs242557 Variant is Associated with Hippocampus Tau Uptake on 18F-AV-1451 PET in Non-Demented Elders.

In Vivo <scp><sup>18</sup>F‐Florzolotau</scp> Tau Positron Emission Tomography Imaging in Parkinson's Disease Dementia

Q351R MAPT mutation is associated with a mixed 3R/4R tauopathy and a slowly progressive cognitive, behavioural and parkinsonian syndrome

Feasibility of 18F-Florzolotau Quantification in Patients with Alzheimer's Disease Based on an MRI-free Tau PET Template

In Vivo F-18-Florzolotau Tau Positron Emission Tomography Imaging in Parkinson's Disease Dementia

International consensus on the use of tau PET imaging agent 18 F-flortaucipir in Alzheimer’s disease

Associations of [18F]-APN-1607 Tau PET Binding in the Brain of Alzheimer’s Disease Patients With Cognition and Glucose Metabolism

Study Of Tau Deposition In Patients Of Alzheimer'S Disease With [F-18]-Apn-1607 Pet Tracer And Its Relationship With Cerebral Glucose Metabolism

18F-MK6240 PET imaging of tau protein in Alzheimer′s disease and cognitive correlation analysis

<SUP>18</SUP>F-Florzolotau Positron Emission Tomography Imaging of Tau Pathology in the Living Brains of Patients with Corticobasal Syndrome

Study on tau related disease pattern of Alzheimer′s disease based on 18F-APN-1607 PET imaging

Clinical and Pathological Features of FTDP-17 with MAPT p.K298_H299insQ Mutation

The Imaging Features and Clinical Associations of a Novel Tau PET Tracer—18F-APN1607 in Alzheimer Disease

Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age–related tauopathy and Alzheimer's disease